ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma

Xiao, Zheng; Liu, Xiaoyan; Mo, Yixiang; Chen, Weibo; Zheng, Shizhong*; Yu, Yingwei*; Weng, Huiwen*广州中医药大学; 南方医科大学; 中山大学; 1; 5
Journal of Medical Biochemistry2023DOI: 10.5937/jomb0-39234
7阅读
引用收藏
分享

摘要

Background: As the most common primary malignant intracranial tumor, glioblastoma has a poor prognosis with limited treatment options. It has a high propensity for recurrence, invasion, and poor immune prognosis due to the complex tumor microenvironment.Methods: Six groups of samples from four datasets were included in this study. We used consensus ClusterPlus to establish two subgroups by the EMT-related gene. The difference in clinicopathological features, genomic characteristics, immune infiltration, treatment response and prognoses were evaluated by multiple algorithms. By using LASSO regression, multi-factor Cox analysis, stepAIC method, a prognostic risk model was constructed based on the final screened genes.Results: The consensusClusterPlus analyses revealed two subtypes of glioblastoma (C1 and C2), which were characterized by different EMT-related gene expression patterns. C2 subtype with the worse prognosis had the more malignant clinical and pathology manifestations, higher Immune infiltration and tumor-associated molecular pathways scores, and poorer response to treatment. Additionally, our EMT-related genes risk prediction model can provide valuable support for clinical evaluations of glioma.Conclusions: The assessment system and prediction model displayed good performance in independent prognostic risk assessment and individual patient treatment response prediction. This can help with clinical treatment decisions and the development of effective treatments.

学科与关键词

关键词
epithelial mesenchymal transitiongliomaimmunotherapyrisk scoretumor microenvironment
相关
加载中…
  • Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
    Zhang, Chunlong; Zhang, Yuxi; Tan, Guiyuan; Mi, Wanqi; Zhong, Xiaoling; Zhang, Yu; Zhao, Ziyan; Li, Feng*; Xu, Yanjun*; Zhang, Yunpeng*Frontiers in Immunology, 2022, 13: 853074.被引 1
  • Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma
    Zhang, Sibin; Xiao, Xu; Wang, Yu; Song, Tianjun; Li, Chenlong; Bao, Hongbo; Liu, Qing; Sun, Guiyin; Sun, Xiaoyang; Su, Tianqi; Fu, Tianjiao; Wang, Yujie; Liang, Peng*Frontiers in Genetics, 2022, 13: 899125.被引 2
  • Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma
    Ma, Shuai; Wang, Fang; Wang, Nan; Jin, Jiaqi; Ba, Yixu; Ji, Hang; Du, Jianyang*; Hu, Shaoshan*Frontiers in Neurology, 2022, 13: 886913.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Medical Biochemistry
发表日期
2023
卷期
第 42 卷, 第 1 期
页码
122-137
DOI
10.5937/jomb0-39234
语言
SERBIAN
成果收录
SCIE

作者

  • X

    Xiao, Zheng (第一作者)

    southern med univ

  • L

    Liu, Xiaoyan

    1 · 5

查看全部 7 位作者收起作者
  • M

    Mo, Yixiang

    southern med univ

  • C

    Chen, Weibo

    southern med univ

  • Z

    Zheng, Shizhong (通讯)

    southern med univ

  • Y

    Yu, Yingwei (通讯)

    2 · guangzhou univ chinese med

  • W

    Weng, Huiwen (通讯)

    1 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417